A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2023-04-11
AEs
3
Serious
1
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-10-08 (study day 161); relationship: not assessed
moderate
assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-12-12 (study day 226); relationship: not assessed
severe
serious
assessed
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-06-14 (study day 411); relationship: N; serious criteria: hospitalization
Data queries
No data queries.